Shares of clinical-stage biotech MoonLake Immunotherapeutics (NASDAQ: MLTX) were up more than 12% as of 11 a.m. on Tuesday. The company’s stock is up more than 466% so far this year.
MoonLake focuses on inflammatory diseases. Its lead asset is sonelokimab, a nanobody therapy that it is testing against several inflammatory conditions. The company appears to be benefiting from a competitor’s woes. On Monday, Acelyrin saw its shares plummet after the biotech company said that its therapy izokibep did not meet statistical significance in a phase 2b/3 trial to treat moderate-to-severe hidradenitis suppurative (HS), a condition that causes small, painful lumps to form under the skin. MoonLake has its own HS therapy, sonelokimab, which is in a phase 2 trial. The company gave positive news on the 12-week readout from the trial and said it expects to announce 24-week data in the middle of next month.
MoonLake has said it sees HS as a potential market of $10 billion a year, and with sonelokimab, it may have a best-in-class asset to treat the disease. Investors will want to see the results of the 24-week readout from its current trial to treat HS. The company is expecting the therapy to be ready to enter three phase 3 trials next year, including one for HS, one for psoriatic arthritis, and one for psoriasis.
The company may be a strong buyout candidate. It doesn’t have any revenue yet, but sonelokimab’s promise should be enough to interest another company. As of the second quarter, MoonLake said it had $501.8 million in cash, enough to fund operations for several years.
10 stocks we like better than MoonLake Immunotherapeutics
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and MoonLake Immunotherapeutics wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of September 11, 2023
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
